Relafen 750, the advanced preparation of naproxen, represents a fascinating case from a biochemical pharmacy perspective. Its process of action, mainly involving inhibition of cyclooxygenase enzymes – COX-1 and COX-2 – contributes to significant reduction in prostaglandin creation. Considering a